Sam Brusco, Associate Editor11.02.23
Silk Road Medical has named Chas McKhann as its new CEO, effective immediately.
McKhann has over 25 years of experience in the medical device industry, including C-suite roles at seven public and private companies. Most recently, he was president and CEO of Apollo Endosurgery, which was acquired by Boston Scientific in April 2023.
Prior to Apollo Endosurgery, McKhann was chief commercial officer at Rox Medical, where he developed commercial strategy for a novel hypertension therapy. He was also chief commercial officer at Torax Medical (acquired by Johnson & Johnson in 2017) and Intersect ENT (acquired by Medtronic in May 2022).
Other roles included CEO at Apnex Medical—developer of a hypoglossal nerve stimulator for obstructive sleep apnea—global head of marketing of cardiac rhythm management at Boston Scientific, and director of marketing at Cordis (then a unit of Johnson & Johnson). At Cordis, McKhann was the marketing lead for CYPHER, the first cardiac drug-eluting stent. He began his career as a strategy consultant at SCA Consulting and McKinsey & Company.
McKhann succeeds Erica Rogers, who has retired from the president and CEO role and will stay on as an advisor to Silk Road’s board.
“I am thrilled to join Silk Road Medical as the company’s CEO,” McKhann told the press. “I look forward to working closely with the leadership team and Board of Directors to build upon Silk Road’s track record of growth, advance the company’s progress toward establishing TCAR as the minimally invasive standard of care in carotid artery disease, and continue delivering on the company’s mission to reduce the risk of stroke and its devastating impact for patients.”
Silk Road Medical has pioneered TransCarotid Artery Revascularization (TCAR), a new approach to treat carotid artery disease. TCAR combines the surgical principles of neuroprotection with minimally invasive endovascular techniques to treat carotid artery blockages that risk causing a stroke.
McKhann has over 25 years of experience in the medical device industry, including C-suite roles at seven public and private companies. Most recently, he was president and CEO of Apollo Endosurgery, which was acquired by Boston Scientific in April 2023.
Prior to Apollo Endosurgery, McKhann was chief commercial officer at Rox Medical, where he developed commercial strategy for a novel hypertension therapy. He was also chief commercial officer at Torax Medical (acquired by Johnson & Johnson in 2017) and Intersect ENT (acquired by Medtronic in May 2022).
Other roles included CEO at Apnex Medical—developer of a hypoglossal nerve stimulator for obstructive sleep apnea—global head of marketing of cardiac rhythm management at Boston Scientific, and director of marketing at Cordis (then a unit of Johnson & Johnson). At Cordis, McKhann was the marketing lead for CYPHER, the first cardiac drug-eluting stent. He began his career as a strategy consultant at SCA Consulting and McKinsey & Company.
McKhann succeeds Erica Rogers, who has retired from the president and CEO role and will stay on as an advisor to Silk Road’s board.
“I am thrilled to join Silk Road Medical as the company’s CEO,” McKhann told the press. “I look forward to working closely with the leadership team and Board of Directors to build upon Silk Road’s track record of growth, advance the company’s progress toward establishing TCAR as the minimally invasive standard of care in carotid artery disease, and continue delivering on the company’s mission to reduce the risk of stroke and its devastating impact for patients.”
Silk Road Medical has pioneered TransCarotid Artery Revascularization (TCAR), a new approach to treat carotid artery disease. TCAR combines the surgical principles of neuroprotection with minimally invasive endovascular techniques to treat carotid artery blockages that risk causing a stroke.